# PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

> **NCT03065400** · PHASE2 · COMPLETED · sponsor: **John Mascarenhas** · enrollment: 10 (actual)

## Conditions studied

- Chronic Phase Myelofibrosis
- Primary Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
- Polycythemia Vera

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03065400
- **Lead sponsor:** John Mascarenhas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-14
- **Primary completion:** 2020-05-28
- **Final completion:** 2020-05-28
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-06-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03065400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03065400, "PD-1 Inhibition in Advanced Myeloproliferative Neoplasms". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03065400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*